Nanoparticles Contract Manufacturing Market Report 2026

The nanoparticles contract manufacturing market size has grown rapidly in recent years. It will grow from $3.67 billion in 2025 to $4.13 billion in 2026 at a compound annual growth rate (CAGR) of 12.7%. The growth in the historic period can be attributed to early adoption of nanomedicine, limited in-house manufacturing capacity, rising research collaborations, initial development of lipid nanoparticles, growth in pre-clinical nanotechnology studies.

The nanoparticles contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $6.38 billion in 2030 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to expansion of mrna vaccine manufacturing, increasing biotech outsourcing demand, advancements in nanoparticle engineering, rising investments in nanotechnology infrastructure, growth of precision medicine applications. Major trends in the forecast period include rising outsourcing of nanoparticle production, increasing adoption of lipid nanoparticles in drug delivery, expansion of clinical-scale manufacturing capabilities, growing demand for customized nanoparticle formulations, increased focus on quality compliance and regulatory alignment.

The surge in research investments is expected to drive the growth of the nanoparticle contract manufacturing market. Research investments refer to the allocation of financial resources toward activities that generate new knowledge, advance scientific understanding, develop innovative technologies, or address specific challenges. Factors such as the emphasis on innovation, awareness of societal challenges, policy support, government funding initiatives, and long-term planning have contributed to the rise in research investments. These investments are critical for advancing nanoparticle contract manufacturing by enabling technological innovation, quality control, scalability, cross-disciplinary collaboration, and market expansion. For instance, in April 2023, the House of Commons, a UK-based governing body, reported that the Chancellor announced a significant increase in public Research and Development (R&D) expenditures, aiming to raise the budget to £22 billion ($27.64 billion) for fiscal year 2024-2025 from roughly £9 billion ($11.3 billion) in the previous year, equivalent to 0.8% of GDP, demonstrating a commitment to enhancing domestic R&D and fostering innovation. Therefore, the rise in research investments is fueling the growth of the nanoparticle contract manufacturing market.

Major companies operating in the nanoparticle contract manufacturing market are focusing on innovative technologies, such as commercial formulation systems, to enhance the efficiency of nanoparticle-based product development and production. Commercial formulation systems provide comprehensive platforms for clinical and commercial manufacturing while ensuring scalability, safety, and regulatory compliance. For instance, in July 2023, Cytiva, a US-based life sciences solutions provider, launched the NanoAssemblr commercial formulation system. The system reduces cross-contamination risk through a single-use fluid path, supports multiple lipid nanoparticle products in one facility, minimizes downtime for cleaning, and incorporates 21 CFR Part 11-compliant software for electronic batch records, in-process flow monitoring, and automated priming, calibration, formulation, and in-line dilution.

In May 2025, PCI Pharma Services, a US-based provider of sterile fill-finish and advanced drug delivery solutions, acquired Ajinomoto Althea for an undisclosed amount. This acquisition expands PCI’s aseptic fill-finish capacity, enhances its advanced modality manufacturing capabilities including nanoparticles, mRNA, peptides, and antibody-drug conjugates, and establishes a large-scale U.S. hub for end-to-end injectable drug product development. Ajinomoto Althea is a US-based provider of sterile fill-finish services, custom biologics manufacturing, and complex injectable formulation capabilities, supporting advanced therapies such as nanoparticles and high-potency biologics.

Major companies operating in the nanoparticles contract manufacturing market are Evonik Industries AG, CordenPharma International GmbH, Ajinomoto Bio-Pharma Services, BioVectra Inc., Fortis Life Sciences, LSNE Contract Manufacturing, Precision NanoSystems Inc., Ardena Holding NV, American Elements, Polymun Scientific Immunbiologische Forschung GmbH, Hitachi Chemical Advanced Therapeutics Solutions LLC, Axolabs GmbH, Cytodiagnostics Inc., Encapsula NanoSciences LLC, Nanochemazone, TechNano India, Lonza, Phosphorex, TRANSFERRA Nanosciences Inc, DIANT Pharma, Nano Labs Corporation, Nanoscale Corporation.

North America was the largest region in the nanoparticles contract manufacturing market in 2025. The regions covered in the nanoparticles contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nanoparticles contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have created cost pressures in the nanoparticles contract manufacturing market by raising the prices of imported raw materials, specialized equipment, and high-purity chemicals required for nanoparticle production. Therapeutics, vaccines, and lipid nanoparticle segments are most affected, particularly in North America and Asia-Pacific where global sourcing is critical. These trade barriers have increased manufacturing costs and extended production timelines. However, tariffs are encouraging domestic CMOs to expand capacity and invest in localized nanoparticle manufacturing infrastructure.

The nanoparticles contract manufacturing market research report is one of a series of new reports that provides nanoparticles contract manufacturing market statistics, including nanoparticles contract manufacturing industry global market size, regional shares, competitors with a nanoparticles contract manufacturing market share, detailed nanoparticles contract manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the nanoparticles contract manufacturing industry. This nanoparticles contract manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nanoparticle contract manufacturing refers to the outsourcing of nanoparticle production to third-party manufacturers or contract manufacturing organizations (CMOs). This approach provides flexible solutions across various industries, offering customized nanoparticle formulations and specialized expertise to meet specific application needs and foster innovation in multiple fields.

The main types of nanoparticles in the contract manufacturing market include metal nanoparticles, lipid nanoparticles, and other nanoparticles. Metal nanoparticles are extremely small metal particles, typically ranging from 1 to 100 nanometers in size. Manufacturing is carried out at commercial, clinical, and pre-clinical scales for applications such as therapeutics, diagnostics, and vaccines. These services are utilized by end users including pharmaceutical companies and biotechnology firms.

The nanoparticle contract manufacturing market includes revenues earned by entities by providing services such as custom synthesis, scale-up production, and surface modification and functionalization and related drug delivery nanoparticles, diagnostic nanoparticles, cosmetic nanoparticles, and electronic nanoparticles. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.